Wang-Zhong Li

List of Publications by Year
in descending order

34	474	759233	794594
papers	citations	12 h-index	19 g-index

35	35	35	479
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development and validation of an endoscopic imagesâ€based deep learning model for detection with nasopharyngeal malignancies. Cancer Communications, 2018, 38, 1-11.	9.2	43
2	Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage IIIâ€“IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 716-726.	10.7	42
3	The CXCL5/CXCR2 axis contributes to the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by activating ERK/GSK-3Î²/snail signalling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 85.	8.6	36
4	The prognostic significance of carcinoma-associated fibroblasts and tumor-associated macrophages in nasopharyngeal carcinoma. Cancer Management and Research, 2018, Volume 10, 1935-1946.	1.9	34
5	Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis. European Radiology, 2021, 31, 4764-4773.	4.5	29
6	Deep learning radiomics of dual-energy computed tomography for predicting lymph node metastases of pancreatic ductal adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1187-1199.	6.4	28
7	Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 120-130.	0.8	27
8	Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity scoreâ€matched analysis. Cancer Communications, 2018, 38, 1-10.	9.2	26
9	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Metaâ€Analysis. Frontiers in Oncology, 2021, 11, 650292.	2.8	22
10	Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma. JAMA Oncology, 2022, 8, 706.	7.1	22
11	Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy. JAMA Oncology, 2022, 8, 553.	7.1	21
12	The plasma Epsteinâ€“Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878233.	3.2	15
13	A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. Clinical Cancer Research, 2021, 27, 4186-4194.	7.0	15
14	Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virusâ€“Related Nasopharyngeal Carcinoma. JAMA Network Open, 2021, 4, e2124721.	5.9	14
15	MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it. Radiotherapy and Oncology, 2020, 145, 101-108.	0.6	12
16	Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database. Oral Oncology, 2021, 117, 105284.	1.5	12
17	Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up. Journal of Cancer, 2018, 9, 3023-3031.	2.5	10
18	Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. Biology of Sex Differences, 2021, 12, 18.	4.1	10

#	Article	IF	Citations
19	A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma. Journal of Inflammation Research, 2021, Volume 14, 817-828.	3.5	10
20	Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2231-2243.	2.5	9
21	Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy. ESMO Open, 2021, 6, 100004.	4.5	6
22	A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy. PLoS ONE, 2017, 12, e0182963.	2.5	6
23	Individualized clinical target volume delineation and efficacy analysis in unilateral nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT): 10-year summary. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1931-1942.	2.5	6
24	Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy. Journal of Inflammation Research, 2021, Volume 14, 2225-2237.	3.5	5
25	Prognostic value of early radiological response to firstâ€line platinumâ€containing chemotherapy in patients with metastatic nasopharyngeal carcinoma. Cancer Medicine, 2020, 9, 920-930.	2.8	4
26	Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.. Journal of Clinical Oncology, 2021, 39, 6044-6044.	1.6	4
27	Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma. Frontiers in Oncology, 2020, 10, 537318.	2.8	3
28	Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. Frontiers in Oncology, 2021, 11, 625534.	2.8	2
29	Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study.. Journal of Clinical Oncology, 2021, 39, 521-521.	1.6	1
30	Educational disparities in nasopharyngeal carcinoma survival: Temporal trends and mediating effects of clinical factors. Clinical and Translational Medicine, 2020, 10, e134.	4.0	0
31	Comparison between lobaplatin and cisplatin plus 5-fluorouracil combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phase III clinical trial.. Journal of Clinical Oncology, 2018, 36, 6029-6029.	1.6	0
32	Prognostic models for prediction of overall survival after first-line platinum-based chemotherapy for primary metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2019, 37, e17501-e17501.	1.6	0
33	Trajectories of EBV DNA and identifying the potential long-term survivors in metastatic nasopharyngeal carcinoma. American Journal of Cancer Research, 2021, 11, 3946-3955.	1.4	0
34	Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinomaâ€”Reply. JAMA Oncology, 0, , .	7.1	0